Adaptyx Biosciences is a technology company.
Adaptyx Biosciences is a technology company.
Adaptyx Biosciences has raised $14.0M across 1 funding round.
Adaptyx Biosciences has raised $14.0M in total across 1 funding round.
Adaptyx Biosciences has raised $14.0M in total across 1 funding round.
Adaptyx Biosciences's investors include ARCH Venture Partners, Atomic, Coatue, Future Ventures, Insight Partners, Overwater Ventures, RA Capital, Two Sigma Ventures, Anne Wojcicki.
Adaptyx Biosciences is a biotech startup developing a programmable biowearable patch for continuous, multi-analyte molecular monitoring using synthetic DNA-based molecular switches.[1][2] The patch analyzes interstitial fluid to track biomarkers like hormones, glucose, drugs, electrolytes, and proteins in real-time, streaming data to AI algorithms for clinician dashboards and insights that enable earlier interventions in clinical settings and everyday health.[1][2][3] It targets patients with conditions like heart failure, reducing hospital readmissions by detecting issues weeks early, and serves clinicians, hospitals, and consumers by replacing lab draws and clinic visits with always-on monitoring.[2][5] Founded in 2022 in Menlo Park, CA, the company has raised $23M in funding, completed human feasibility studies, validated 12+ analytes, and is pursuing FDA clearance while showing strong growth via investor backing and Stanford-licensed patents.[1][2][3]
Adaptyx emerged from 17 years of Stanford-led research, with co-founders—including CEO Vig—who collaborated there to address the lack of continuous biochemical data in healthcare.[2][5] The idea crystallized around synthetic DNA molecular switches, resulting in 25 patent applications (9 families exclusively licensed from Stanford) after cracking real-time biomarker tracking.[2][5] Pivotal early traction includes validating 12+ analytes, launching human feasibility studies, and securing $23M total funding since 2022, highlighted by a $14M seed round in 2025 led by Interlagos with participation from Overwater Ventures, Starbloom Capital, Stanford University, Chan Zuckerberg Biohub, and others.[1][3] This momentum stems from a mission to prevent complications like heart failure readmissions, humanizing their drive: "Every patient deserves to see their next birthday."[5]
Adaptyx rides the convergence of wearables, synthetic biology, and AI-driven precision medicine, shifting healthcare from episodic snapshots (lab draws, check-ins) to continuous streams amid rising chronic disease burdens like heart failure affecting 8M patients.[2][5] Timing aligns with post-glucose-monitor maturity, where multi-analyte needs (hormones, drugs) demand scalable biosensors; market forces like AI analytics growth and FDA wearable approvals favor rapid scaling.[1][3] It influences the ecosystem by licensing Stanford IP, attracting top VCs (e.g., Chan Zuckerberg Biohub), and enabling "always-on" care that cuts costs/readmissions, paving the way for personalized therapies in wellness and narrow-index drugs.[2][3]
Adaptyx is poised for FDA clearance milestones, expanding from clinical (heart failure, acute therapies) to consumer wellness with more analytes and AI refinements.[1][2] Trends like AI-optimized biosensors and interstitial fluid tech will accelerate adoption, potentially dominating multi-analyte monitoring as funding fuels commercialization.[3] Its influence may evolve into a platform leader, licensing switches or partnering with pharma for drug monitoring, ultimately redefining proactive healthcare from reactive patches to ecosystem-wide intelligence—delivering the continuous data that saves lives, as their founders envisioned.[5]
Adaptyx Biosciences has raised $14.0M across 1 funding round. Most recently, it raised $14.0M Seed in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2025 | $14.0M Seed | ARCH Venture Partners, Atomic, Coatue, Future Ventures, Insight Partners, Overwater Ventures, RA Capital, Two Sigma Ventures, Anne Wojcicki |